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Objective: To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive
vagus nerve stimulation (nVNS) responsiveness in migraineurs.
Methods: This double-blinded, sham-controlled study enrolled 48 subjects and measured headache
severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/
month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of
inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of
adjunctive nVNS compared to sham stimulation and suitably matched controls.
Results: No significant differences were observed at baseline and after 2 months for headache severity,
total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between
verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the
verum nVNS group and circulating pro-inflammatory IL-1b was elevated significantly in the sham group
compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups
compared to healthy controls, but not at 2 months follow-up [p< 0.05]. Concentrations of high-mobility
group box-1 (HMGB-1), IL-6, tumor-necrosis factor-a (TNF-a), leptin, adiponectin, ghrelin remained
unchanged [p> 0.05]. No severe device-/stimulation-related adverse events occurred.
Conclusion: 2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/
month. Pro-inflammatory IL-1b plasma levels [inter-ictal] were higher in sham-treated migraine patients
compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-a, leptin] and anti-inflammatory [IL-10,
adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in
migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by
pre-analytic variables warranting large-scale biobank-based systematic investigations [omics].
© 2019 Elsevier Inc. All rights reserved.P, cholinergic anti-inflammatory pathway; CGRP, Calcitonin gene related peptide; CM, chronic migraine; CRP, C-reactive
s; ELISA, enzyme-linked immunoassay; EM, episodic migraine; HMGB, high mobility group box; IL, interleukins; TNF,
ociety; MIDAS, migraine disability scale; nVNS, cervical non-invasive vagal nerve stimulation; PSQI, Pittsburgh Sleep
ationId¼trial.HTML&TRIAL_ID¼DRKS00009944. This study was registered on 08.02.2016 at the German Register for
ivision of Medical Psychology (NEMO Neuromodulation of Emotions), University Hospital Bonn, Rheinische Friedrich-
.M. Kinfe).
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HTML&TRIAL_ID¼DRKS00009944.Cervical non-invasive vagus nerve stimulation (nVNS) emerged
as an adjunctive treatment option for the abortive and preventive
use in episodic and chronicmigraine. Both uncontrolled explorative
studies and randomized-controlled trials have effectively under-
pinned the impact and safety of nVNS for the treatment of migraine
and other primary headache disorders with a more favorable
responsiveness for episodic migraine subtype [1e4]. In addition,
several explorative human studies determined a variety of neuro-
inflammatory markers in serum (jugular or peripheral vein) and
found ictally increased interleukin (IL)-1b, IL-6, tumor necrosis
factor (TNF)-a, endocan and claudin-5, in migraine patients
compared to healthy controls [5e7].
In humans, the effect of surgically implanted VNS devices on the
neuro-immune host response was assessed in two small-scale
uncontrolled clinical studies with refractory focal seizures and re-
fractory depression. The inflammatory assessments demonstrated
significant changes in plasma cytokine levels (IL-6, IL-8, TNF-a,
TGF-b) after 3 months of VNS compared to baseline [8,9]. In healthy
humans, Lerman et al., applied nVNS and assessed the peripheral
neuro-immune axis. Significantly suppressed levels of pro-
inflammatory IL-1b, TNF-a, IL-8 and macrophage attractant pep-
tides were quantified in the nVNS group compared to sham stim-
ulation indicating an anti-inflammatory potential of nVNS
treatment [10].
An increasing body of experimental evidence suggests that
vagal nerve stimulation modulates immune response and systemic
inflammation by influencing cytokine release through the cholin-
ergic anti-inflammatory reflex, thus re-balancing the neuro-
immune axis [11,12]. The parasympathetic cholinergic response,
which is in part regulated by reciprocal anatomic connectivity of
the afferent vagal nerve fibers and the hypothalamic-pituitary axis
(HPA), impacts the neuro-immune axis. The neuro-inflammatory
pathway is modulated by the interaction of pro- and anti-
inflammatory mediators (cytokines, chemokines), including the
interleukins (IL)-1b, IL-6, IL-8, IL-10, IL-13, interferon-g (IFN-g),
TNF-a and HMGB-1 protein. This modulation is likely promoted by
the neuro-immune interaction between peripheral immune cells,
such as mononuclear monocytes, and the autonomic nervous sys-
tem [13,14].
However, clinical data from human migraine studies investi-
gating the impact of VNS on the neuro-inflammatory axis are
lacking [1,15].
In this double-blinded, sham-controlled study, we firstly
attempted to test the feasibility of peripheral molecular profiling
based on immune-assays in refractory migraine patients treated
with adjunctive nVNS. This feasibility study assessed the clinical
outcome of nVNS treated migraineurs based on score-evaluation
(severity, frequency, functional capacity) and on the neuro-
immune host response (pro- and anti-inflammatory cytokines,
adipokines) under a double-blinded sham-controlled study design.
Materials and methods
Study design
This double-blinded, sham-controlled cohort study included
patients with refractory episodic migraine (EM) and chronic
migraine (CM) and compared nVNS to sham stimulation. This study
protocol was performed according to the guidelines of the Helsinki
declaration and was approved by the Ethics Committee of the
Medical Faculty, University of Bonn (No.: 259/15) and indexed at
the German Register for Clinical Trials (DRKS ID 00009944) on
08.02.2016.Study population and clinical assessment
Patients were referred by a headache specialist (neurologist/
anesthesiologist) with their diagnosis and refractory condition
(defined as having failed at least four classes of preventive medi-
cations) confirmed by a multidisciplinary pain board according to
the International Classification of Headache Disorders criteria (3rd
edition, beta version) [16e19]. The inclusion and exclusion criteria
are outlined in Table 1.
The following baseline characteristics of patients were assessed:
headache severity with a visual analogue scale (VAS), headache
frequency (number of headache days per month; number of total
attacks/month and number of mild e moderate e severe catego-
rized attacks/month). Depending on head pain intensity (quantified
by VAS; visual analogue scale), migraine attacks were categorized
as severe (severe¼VAS 7-10/10), moderate (moderate¼VAS 4-6/
10) or mild (mild¼ VAS 1-3/10). Pain relief was defined as a 50%
reduction in severity and/or frequency. In addition, relevant
migraine co-morbidities such as impaired sleep quality assessed by
the Pittsburgh Sleep Quality Index (PSQI), severity of depressive
symptoms assessed by the Beck Depression Inventory (BDI), impact
of headache on life by the Migraine Disability Assessment (MIDAS),
and the metabolic state (Body Mass Index (BMI)) were recorded
[20e22]. Patients were instructed to record severity and frequency
on a daily basis (headache diary) within the study period. Data for
all study parameters including head pain intensity/frequency were
recorded from the patients’ headache diaries and through in-
terviews during the outpatient visits after two months during the
inter-ictal period (48 h apart from an attack). Data of all reported
and treated attacks within the two months of nVNS therapy were
pooled and analyzed. Peripheral blood samples were collected from
the cubital vein during the inter-ictal period (defined as 48 h from
the last attack) at a defined time (08:00e09:00 a.m.).
All patient-reported migraine scores, peripheral blood collec-
tion and analysis were performed again after two months of nVNS
treatment by an independent third party to assure a double-
blinded design. Adjunctive medication remained unchanged four
weeks prior to baseline and within the study period.
Baseline characteristics of the study cohort
The study population included 48 subjects consisting of 30
migraine patients and 18 age-/gender-matched healthy controls. Of
the 30 migraineurs, 29 were female and one was male, with an
average age of 46.96 years (range, 27e66 years). Episodic migraine
(EM) was diagnosed in 19 patients (14 without aura; fivewith aura)
and chronic migraine (CM) was diagnosed in the other 11 patients
(five with aura; six without aura). An impaired functional state was
present in the migraineurs affecting sleep architecture (non-sleep
onset of attacks) in 21/30 patients (average PSQI global: 7; average
MIDAS Grade: IV/MIDAS score: 54; BDI score: 15; BMI: 23.2).
Eighteen healthy controls (HC) were recruited from the local
population by means of online advertisement, public postings and
contacts to assisted living facilities. Subjects were free of any cur-
rent physical or psychiatric illness as assessed by medical history
and were assessed at baseline and follow-up (score evaluation and
serum sampling for cytokine assay). HC participants did not receive
nVNS treatment. Baseline assessment of the healthy control group
(HC) demonstrated similar characteristics compared to the
migraine group (HC group: 15 female/3 male; mean age: 43.16
years, ranging from 22 to 59 years; BMI: 24.2). Adjunctive pro-
phylactic and abortive medicationwas unchanged one month prior
Table 1
Inclusion and exclusion criteria according to the study protocol.
Inclusion criteria Exclusion criteria
➢ chronic refractory headache disorder according to the International Classification of
Headache Disorders criteria (3rd edition, beta version) age equal/greater than 18
➢ informed consent (Study, nVNS)
➢ refractory to medical and/or behavioural therapy
➢ eligible for vagus nerve stimulation
➢ willingness to a defined follow-up interval
➢ stable pain medication four weeks prior to nVNS
➢ no informed consent
➢ other concomitant neuropsychiatric comorbidity not adequately classified
and/or requiring specific diagnosis/treatment
➢ pregnancy
➢ Previously performed invasive, noninvasive and ablative procedures
➢ not willing to complete pain diary regarding severity and frequency
➢ intracranial and cervical pathologies confirmed by magnetic resonance scan
➢ medication overuse headache
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entire study.
Table 2 summarizes baseline characteristics of 26 migraine pa-
tients, who accomplished the two months visit (four patients
excluded due to study protocol deviation).Determination of peripheral cytokines
Different cytokines such as IL-1b, TNF-a, IL-6 and IL-10 were
quantified in serum of the control and migraine patients by
enzyme-linked immunoassays. Serum IL-1b, TNF-a and IL-6 high
sensitivity ELISA kits were employed to quantify the levels of these
cytokines by following the manufacturer's instructions (Catalog #
HSLB00D, HSTA00E and HS600B respectively; R&D Systems, MN,
USA). The high sensitive ranges were 0.1e8 pg/mL, 0.2e10 pg/mL
and 0.2e10 pg/mL, respectively.
Serum IL-10 was quantified by BD OptEIA™ ELISA kit from BD
Biosciences (Catalog # 550613, San Jose, CA, USA) within an assay
range of 2e500 pg/mL. HMGB-1 ELISA kit was supplied by IBL In-
ternational (Catalog # ST51011, Hamburg, Germany) and was per-
formed in the high sensitive range 0.313e10 ng/mL. Human total
adiponectin and leptin ELISA kits were obtained from R&D SystemsTable 2
Baseline characteristics according to migraine subtype, gender, age, relevant co-morbid
migraine; EM ¼ episodic migraine; þ/ ¼ with/without aura; TRIP ¼ triptans; TCA ¼ tr
hibitor; ACD ¼ anticonvulsant drug (i.e. topiramate); NSAID ¼ nonsteroidal anti-inflam
domperidone); CORT ¼ cortisone; THC ¼ tetrahydrocannabinol, BDI ¼ Beck depression i
Pittsburgh sleep quality index.
No. Sex Age (year) BMI kg/m2 Type Attacks per
month
Headache days
per month
Pr
m
1 f 53 23,0 EMþ 10 14 BB
2 f 49 20,8 CMþ 12 20 0
3 f 42 24,3 EM- 9 14 0
4 f 37 27,4 EM- 10 10 0
5 f 63 19,5 EM- 3 7 0
6 f 30 19,0 EMþ 12 12 0
7 f 66 24,3 EM- 11 13 0
8 f 36 23,4 CM- 30 30 SS
9 f 40 20,9 CM- 10 30 SN
10 f 45 19,6 EM- 3 8 TH
11 f 52 22,3 EMþ 7 7 0
12 m 27 26,2 CM- 25 17 AC
13 f 50 18,8 CMþ 16 19 0
14 f 54 23,4 EM- 12 15 0
15 f 48 22,5 EM- 12 12 0
16 f 55 23,3 EM- 15 15 BB
17 f 58 19,7 EM- 2 8 0
18 f 38 26,5 CM- 30 30 BB
19 f 50 21,7 EM- 12 30 0
20 f 45 19,3 EM- 10 10 0
21 f 51 23,4 EMþ 5 13 0
22 f 27 22,1 EM- 15 15 0
23 f 45 33,9 EMþ 15 15 0
24 f 58 22,7 EM- 12 12 BB
25 f 41 21,3 EM- 5 13 0
26 f 61 33,5 CMþ 30 30 0(Catalog # DRP300 and DLP00, Minneapolis, MN, USA), while
Ghrelin serum levels were determined by ELISA kit obtained from
eBioscience (Catalog # BMS2192, Bender MedSystems GmbH,
Vienna, Austria). The serum levels of these adipokines were
determined by following the manufacturers’ instructions and were
performed within assay ranges of 3.9e250 ng/mL, 15.6e1000 pg/
mL and 15.6e1000 pg/mL, respectively. The lower values of the
assay ranges represent the lowest standard dilutions used and the
sensitivities of these kits were following: IL-1b - 0.063 pg/mL, TNF-
a - 0.049 pg/mL, IL-6 - 0.11 pg/mL, IL-10 - 2 pg/mL, HMGB-1 - 0.2 ng/
mL, adiponectin - 0.891 ng/mL, leptin - 7.8 pg/mL and ghrelin -
11.8 pg/mL.nVNS stimulation pattern and randomization/blinding
The nVNS therapy was self-administered by patients twice daily
(in the morning and late afternoon) bilaterally (one application on
each side). Each application lasted 120 s. Patients were also
instructed to administer one additional bilateral application at the
onset of each headache attack in conjunction to already-prescribed
acute rescue medication (one additional bilateral application was
permitted after 15e30min). The nVNS device (CE-approved;ities, abortive and preventive medications. f ¼ female; m ¼ male; CM ¼ chronic
icyclic antidepressants; SS(N)RI ¼ selective serotonin (noradrenaline) reuptake in-
matory drugs; VA ¼ valproic acid; BB ¼ b-blocker; DA ¼ dopamine-antagonist (i.e.
nventory, BMI ¼ Body mass index, MIDAS ¼ Migraine disability assessment, PSQI ¼
eventive
edication
Abortive
medication
MIDAS score/grade BDI score/grade PSQI score
, VA TRIP, NSAID 42/IV 16/II 7
0 70/IV 23/III 7
0 22/IV 8/0 9
TRIP 84/IV 2/0 3
TRIP 27/IV 4/0 9
0 174/IV 12/0 10
TRIP, NSAID 30/III 18/II 5
RI, ACD TRIP 85/IV 15/II 6
RI TRIP, NSAID 90/IV 19/II 6
C TRIP, NSAID 85/IV 13/0 13
TRIP, NSAID 20/III 6/0 3
D TRIP 65/IV 17/II 4
TRIP 30/IV 8/0 9
TRIP 87/IV 15/II 9
TRIP 23/IV 19/II 8
TRIP 60/IV 20/III 11
TRIP, NSAID 43/IV 11/0 4
TRIP 90/IV 41/IV 15
NSAID, CORT 90/IV 36/IV 10
TRIP 37/IV 18/II 5
NSAID 25/IV 8/0 5
NSAID 30/IV 16/II 13
TRIP 25/II 14/I 9
TRIP, NSAID 54/IV 7/0 12
TRIP 14/II 13/0 5
TRIP 13/I 6/0 5
Fig. 1. Comparison of migraine severity assessed separately for mild [VAS 1-3/10] e
moderate [VAS 4-6/10] e severe [VAS 7-10/10] rated head pain using the visual
analogue scale [VAS] given at the vertical axis. Mild, moderate and severe attacks
between sham nVNS [n¼ 12] and verum nVNS [n¼ 14] group at baseline and follow-
up after 2 months [horizontal axis]. Values represent mean ± SEM and One-way
ANOVA followed by Tukey's multiple comparisons test was used. P value < 0.05 was
considered significant. Although no significant differences were present, mild rated
attacks increased in severity in the sham nVNS group.
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tioned medial to the sternocleidomastoid muscle and lateral to the
larynx. The constant voltage-driven device employed the following
stimulation specifications: 1-ms bursts of 5 kHz sine waves,
repeated every 40ms (25 Hz) with an adjustable stimulation in-
tensity (from 0 to 24 V). A conducting gel was applied in order to
ensure transdermal signal conductivity. Prior to nVNS initiation, all
participants were trained by the same independent and unblinded
instructor for appropriate and standardized use of the nVNS device.
nVNS sham stimulation was achieved by producing a 0.1 KHz
biphasic signal that could be perceived physically without stimu-
lating the vagus nerve or neck muscles.
The randomization schedule was designed by an independent
statistician to assign study participants 1:1 to verum group with
nVNS or sham stimulation. The end of the two months randomized
phase was defined as month 2. Participants, principal investigators
and study coordinators were blinded to treatment assignment
within the randomized phase. Four out of 30 migraine patients
were excluded from the final analysis (verum group: 1 device
dysfunction; sham group: 1 devicemalfunction,1 cold,1 worsening
of head pain requiring change of medication), hence, 26 migraine
(14 verum nVNS versus 12 sham nVNS) and 18 healthy participants
fulfilled the 2 months follow-up visit.
Statistical analysis
Study parameters including migraine severity (VAS), migraine
frequency (headache days, total attacks, mild/moderate/severe at-
tacks per month), functional state (PSQI, BDI, MIDAS, BMI) and
peripheral levels of inflammatory mediators (IL-1b, IL-6, HMGB-1,
TNF-a, leptin, IL-10, adiponectin, ghrelin) at baseline and at follow-
up visit were represented as mean± SEM. Different groups such as
healthy controls, sham and verumwere compared to each other by
using one-way analysis of variance (ANOVA) followed by Tukey's
multiple comparisons test unless otherwise stated. A p-value of less
than 0.05 was considered significant. Pearson's correlation co-
efficients were used to assess linear associations between different
parameters, while Spearman's correlation coefficients were deter-
mined to assess non-linear associations. The results were analyzed
using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Results
Migraine severity
No significant difference was found for mild [F(3,48)¼ 1.45,
p¼ 0.241], moderate [F(3,48)¼ 0.820, p¼ 0.489] and severe
[F(3,48)¼ 1.87, p¼ 0.148] rated head pain between sham and
verum nVNS at baseline and follow-up. Although not statistically
significant, we found an increase of the severity in the sham nVNS
group for mild rated head pain. No significant differences were
found, when comparing baseline and follow-up of verum nVNS
group [mild attacks (VAS): 1.68 ± 0.49 versus 2.5± 0.33; moderate
attacks (VAS): 4.68 ± 0.58 versus 5.43± 0.22; severe attacks (VAS):
8.56± 0.27 versus 7.75± 0.64; p> 0.05] and sham nVNS treated
subjects [mild attack (VAS): 1.38± 0.43 versus 5.95± 3.6; moderate
attacks (VAS): 5.17± 0.53 versus 5.54± 0.26; severe attacks (VAS):
9.13± 0.25 versus 8.63± 0.31; p> 0.05](Fig. 1).
Migraine frequency (headache days per month - attacks per month)
No significant difference was found for the number of headache
days/month [F(3,48)¼ 0.724, p¼ 0.542] and for the total number of
attacks/month [F(3,48)¼ 0.675, p¼ 0.572] between sham and
verum nVNS at baseline and follow-up (Fig. 2A and B).However, categorization of the number of total attacks into mild
e moderate e severe rated attacks demonstrated no significant
difference for the number of mild attacks/month [F(3,48)¼ 0.950,
p¼ 0.424] andmoderate attacks [F(3,48)¼ 0.0429, p¼ 0.988], but a
significant difference was found for the number of severe rated
attacks/months [F(3,48)¼ 2.81, p¼ 0.049] between sham and
verum nVNS at baseline and follow-up. Post hoc Tukey's test
showed a significantly lower number of severe rated attacks/
months after 2 months of nVNS in verum group [verum nVNS
(VAS): 7.64± 1.44 versus 2.93± 1.03; sham nVNS (VAS): 6.75± 1.54
versus 4.79± 1.05; p< 0.05](Fig. 2C).
Fig. 2. Comparison of (A) number of headache days [y-axis] and (B) the number of
total attacks per month [y-axis] between sham [n¼ 12] and verum [n¼ 14] groups at
baseline and follow-up after 2 months [x-axis]. In addition, (C) the number of severe
rated attacks per month were assessed. Values represent mean± SEM and One-way
ANOVA followed by Tukey's multiple comparisons test was used. P value< 0.05 was
considered significant. A significant difference was found for the number of severe
attacks/month between sham and verum group at baseline and follow-up
[F(3,48)¼ 2.81, p¼ 0.049].
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subjective self-rated scores
No significant difference was found for different functional
scores such as BDI grade [F(3,48)¼ 0.827, p¼ 0.486], BDI score
[F(3,48)¼ 2.20, p¼ 0.0996], MIDAS [F(3,48)¼ 1.45, p¼ 0.241], PSQI
[F(3,48)¼ 1.08, p¼ 0.368] and BMI [F(2,41)¼ 0.578, p¼ 0.566] be-
tween sham and verum nVNS group at baseline and after 2 months.So, the functional impairment remained unchanged at baseline and
after 2 months among the verum nVNS group [BDI grade
(1.71± 0.34 versus 1.43± 0.25); BDI score (16.57± 2.77 versus
12.64± 1.85); MIDAS (3.86± 0.1 versus 3.57± 0.25); global PSQI
(8.57± 0.92 versus 7.5± 1.17); p> 0.05] and the sham treated nVNS
cohort [BDI grade (1.58± 0.19 versus 1.17± 0.17); BDI score
(12.75± 1.88 versus 8.67± 1.84); MIDAS grade (3.92± 0.08 versus
3.83± 0.11); global PSQI (6.83± 0.87 versus 6.0± 1.17); p> 0.05].
BMI was similar at baseline and after 2 months nVNS [HC:
24.2± 1.08 vs verum nVNS: 23.7± 1.25 vs sham nVNS: 22.6± 0.779;
p> 0.05] (data not shown).Levels of circulating pro-inflammatory HMGB-1, TNF-a, IL-1b, IL-6
and leptin
A significant difference of pro-inflammatory IL-1b was found
between healthy control, sham and verum nVNS at baseline
and follow-up [F(5,82)¼ 3.51, p¼ 0.006] with a significant increase
of IL-1b in the sham stimulation group compared to the verum
nVNS and healthy controls [HC: 0.11± 0.02 pg/mL versus sham
nVNS: 0.16± 0.06 pg/mL versus verum nVNS: 0.05± 0.01 pg/mL;
p< 0.05] after 2 months. No significant difference was found for
pro-inflammatory HMGB-1 [F(5,82)¼ 1.43, p¼ 0.221], IL-6
[F(5,82)¼ 0.774, p¼ 0.571], TNF-a [F(5,82)¼ 1.31, p¼ 0.266] and
leptin [F(5,82)¼ 0.639, p¼ 0.671] between healthy control, sham
and verum nVNS treated group at baseline and follow-up (Figs. 3
and 4). Further subgroup analysis comparing pooled HMGB-1
values between migraine patients with and without aura demon-
strated similar levels for both groups [aura: 1.93± 0.32 ng/mL
versus non-aura: 2.2± 0.68 ng/mL; p> 0.05] (Fig. 4). Metabolic-
associated leptin remained similar at baseline and follow-up [HC:
23666.67± 4202.21 versus 20244.45± 3225.41 pg/mL; sham nVNS:
24708.33± 5071.47 versus 27991.67± 6587.08 pg/mL; verum nVNS:
31850± 10523.13 versus 34064.29± 9486.9 pg/mL; p> 0.05].
Table 3 provides an overview of the concentrations of these
cytokines and adipokines determined in this study. Assessment of
pre- and post-nVNS IL-1b [baseline: r¼ 0.189; p¼ 0.519 versus
follow-up: r¼0.022; p¼ 0.94] and IL-10 [baseline: r¼ 0.11;
p¼ 0.708 versus follow-up: r¼0.006; p¼ 0.985)] levels showed
no significant correlation or trend with the number of severe at-
tacks per months (Fig. 5AeD).Levels of circulating anti-inflammatory IL-10, adiponectin and
ghrelin
Anti-inflammatory IL-10 significantly differed between the
healthy control, sham nVNS and verum nVNS comparing
baseline and follow-up (F(5,82)¼ 7.41, p¼ 0.0001). After post-hoc
testing, no significant difference was found at baseline and follow-
up in HC, the sham and nVNS groups. However, a significant
difference existed among baseline IL-10 values in HC and
baseline IL-10 levels in sham as well as verum nVNS group and also
follow-up levels of IL-10 in verum nVNS group (Fig. 3D, Table 3).
Follow-up IL-10 levels in HC also significantly differed from
baseline IL-10 levels of both sham and verum groups (HC:
13.78 ± 4.5 pg/mL versus sham nVNS: 59.56 ± 12.44 pg/mL versus
verum nVNS: 64.48± 9.68 pg/mL; p < 0.05), but not at follow-up
after two months of nVNS (HC: 17.04± 3.78 pg/mL versus sham
nVNS: 43.56± 9.3 pg/mL versus verum nVNS: 43.68 ± 10.66 pg/ml;
p> 0.05) (Fig. 3). No significant difference was found for
metabolic-related anti-inflammatory concentrations of adipo-
nectin (F(5,82)¼ 1.27, p¼ 0.285) and ghrelin (F(5,82)¼ 0.744,
p¼ 0.592) between healthy control, sham and verum nVNS groups
at baseline and follow-up (Table 3).
Fig. 3. Comparison of peripheral levels [y-axis] of IL-1b [pg/mL], IL-6 [pg/mL], TNF-a [pg/mL] and IL-10 [pg/mL] between healthy controls [n¼ 18], sham nVNS [n¼ 12] and verum
nVNS [n¼ 14] treated subjects at baseline and follow-up after 2 months. Values represent mean± SEM and One-way ANOVA followed by Tukey's multiple comparisons test was
used. P value< 0.05 was considered significant. Anti-inflammatory IL-10 was significantly lower in healthy controls compared to migraineurs [sham and verum nVNS] at baseline
and follow-up [F(5,82)¼ 7.41, p¼ 0.0001] and pro-inflammatory IL-1b significantly increased in the sham nVNS group at follow-up compared to verum nVNS. Abbreviations:
Interleukin-1, 6, 10 [IL-1b, IL-10, IL-6] and tumor necrosis factor [TNF], HC [healthy controls], ns [not significant].
Fig. 4. A. Comparison of serum levels of pro-inflammatory HMGB-1 [y-axis; ng/mL] between healthy controls [n¼ 18], sham nVNS [n¼ 12] and verum nVNS [n¼ 14] groups at
baseline and follow-up after 2 months [x-axis] demonstrating no significant differences (F(5,82)¼ 1.43, p¼ 0.221). B. Pooled HMGB-1 [y-axis; ng/mL] analysis comparing migraine
with aura (n¼ 16) versus migraine subjects without aura (n¼ 36) demonstrated similar values for migraineurs with and without aura [x-axis]. Values represent median with range
and Mann Whitney U test was used. P value< 0.05 was considered significant. Abbreviations: HMGB-1 [high-mobility group box-1], HC [healthy controls], ns [not significant].
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One device-related adverse event (DAE) was noted for both
groups (dysfunction), while in the sham group two non-device-
related adverse events occurred (1 cold, 1 worsening of headache
requiring changed medication).
Discussion
Summary of the main findings (primary outcomes first followed by
secondary outcomes)
This double-blinded, sham-controlled study demonstrated cer-
vical nVNS to be safe and to effectively reduce the number of severe
attacks per month, while the overall frequency (headache days/
month e total attacks/month) and severity did not differ statisti-
cally between verum and sham nVNS treatment (combined with
pharmacotherapy) in refractory EM and CM patients (with/withoutaura). In our trial, nVNS headache responsiveness was low
compared to the findings of previously published data related to
the utility of nVNS in the acute and preventive treatment of
migraine and cluster headaches [1e4].
Impaired sleep architecture represents a frequently occurring
co-morbidity in migraine. Engstrom et al. provided evidence for a
significant relation between dysfunctional sleep and primary
headache disorders [23,24]. Impaired functional capability in terms
of migraine-associated disturbed sleep architecture, life quality/
disability and clinical depressive symptoms remained unchanged
after two months of nVNS in our cohort. Whether, and to what
extent, decreased headache or improved sleep quality contribute to
the functional outcome in nVNS headache studies remains unclear
and needs further clarification via quantitative measures (poly-
somnography) [23,24]. Due to the possible impact of changes in
medication on headache, sleep patterns and circulating cytokines,
these factors were maintained for the duration of the study.
Table 3
Numeric presentation of baseline and follow-up serum concentrations for healthy controls, sham nVNS and verumnVNS groups of pro- [IL-1b (pg/mL), IL-6 (pg/mL), TNF-a (pg/
mL), HMGB-1 (ng/mL) and leptin (pg/mL)] and anti-inflammatory [IL-10 (pg/mL), adiponectin (pg/mL), ghrelin (pg/mL)] cytokines demonstrating significant differences for
pro-inflammatory IL-1b and anti-inflammatory IL-10. Abbreviations: Interleukin-1b, 6 and 10 [IL-1ß, IL-6, IL-10], tumor necrosis factor [TNF], highmobility group box-1 [HMGB-
1], HC [healthy controls].
healthy control nVNS sham nVNS p-values
baseline/follow-up baseline/follow-up baseline/follow-up
IL-1b (pg/ml) 0.08± 0.02/0.11± 0.02 0.02± 0.01/0.05 ± 0.01 0.02± 0.01/0.16± 0.06 p < 0.05
IL-6 (pg/ml) 2.14± 0.58/2.01± 0.57 2.5± 1.1/2.44 ± 1.18 0.95± 0.19/0.95± 0.14 p> 0.05
IL-10 (pg/ml) 13.78± 4.5/17.04 ± 3.78 64.48± 9.68/43.68 ± 10.66 59.56± 12.44/43.56 ± 9.3 p < 0.05
TNF-a (pg/ml) 0.94± 0.08/0.96± 0.08 0.92± 0.06/0.86 ± 0.04 0.82± 0.08/0.73± 0.07 p> 0.05
HMGB-1 (ng/ml) 1.2± 0.37/1.6± 0.5 1.64± 0.46/1.27 ± 0.33 2.64± 0.89/2.68± 0.65 p> 0.05
Leptin (pg/ml) 23666.67 ± 4202.21/20244.45 ± 3225.41 31850± 10523.13/34064.29± 9486.9 24708.33 ± 5071.47/27991.67 ± 6587.08 p> 0.05
Adiponectin (pg/ml) 7391.68 ± 976.93/7021.68 ± 921.27 9896.43 ± 1209.41/9685 ± 1208.25 8304.17 ± 1330.01/7210 ± 1319.94 p> 0.05
Ghrelin (pg/ml) 3538.49 ± 251.25/3827.747 ± 472.63 3693.12 ± 366.2/4350.55 ± 822.8 4509.76 ± 661.67/3336.94 ± 356.74 p> 0.05
Fig. 5. A-B. Correlation analysis between pre- [A] and post-nVNS [B] levels of pro-inflammatory IL-1b [y-axis; pg/mL] and headache frequency [numbers of severe attacks/month; x-
axis] showing no association with number of severe attacks [baseline: r¼ 0.189; p¼ 0.519 versus follow-up: r¼0.022; p¼ 0.94]. C-D. Assessment of pre- [C] and post-nVNS [D]
concentrations of anti-inflammatory IL-10 [y-axis; pg/mL] levels showed no association with number of severe attacks [baseline: r¼ 0.11; p¼ 0.708 versus follow-up: r¼0.006;
p¼ 0.985]. Abbreviations: IL-1ß [Interleukin-1b], IL-10 [Interleukin 10], HC [healthy controls], ns [not significant].
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the sham group at follow-up, hence nVNSmay have prevented such
a significant upsurge of IL-1b in the verum group at follow-up.
Furthermore, anti-inflammatory IL-10 was significantly elevated
pre-nVNS in migraineurs (verum and sham) compared to healthy
controls, but not post-nVNS treatment. Pro-inflammatory IL-6 and
TNF-a levels demonstrated no significant differences between all
groups at baseline and after 2 months nVNS. Prior to nVNS treat-
ment and within the treatment period, no clinical systemic disease
was observed (C-reactive protein below 0.4mg/dL). IL-1b has been
suspected to evoke activation of cyclo-oxygenase 2 (COX-2) asso-
ciated pathways involving glial cells and neurons of the trigeminal
ganglion (TG). These COX-2 dependent pathways lead to prosta-
glandins release from glial and neuronal trigeminal ganglion (TG)
cells, which exclusively promotes neurons of the TG to immediately
synthesize calcitonin-gene related peptide (CGRP), contrary to IL-
1b, which demonstrated a delayed CGRP release pattern indicative
for a glia-neuron interaction in the TG. Methylprednisoloneantagonized the IL-1b effects, but was found to have no impact on
prostaglandin induced CGRP release [25]. Preclinical evidence in-
dicates that IL-1b and IL-6 interact with intracranial meningeal
nociceptors promoting head pain and disrupted trigemino-
nociceptive signaling [26].
The pro-inflammatory HMGB-1 (DNA-binding peptide), a
member of the damage-associated molecular patterns (DAMPs)
and early recognition marker of inflammation, is overly expressed
extracellularly in the cerebrospinal fluid (CSF) and plasma after
neuronal injury/damage. Elevated circulating HMGB-1 marker has
been associated with cortical spreading depression (CSD) in pre-
clinical models of migraine with aura [27,28]. Interestingly, a cor-
relation has been observed between the HMGB-1 expression and
the number of experimentally induced CSDs with a time-
dependent pattern. HMGB-1 may reflect the bridging link be-
tween migraine aura, CSD and headache pain, by activation of the
trigemino-vascular system leading to attack onset [27e30]. Inva-
sive and non-invasive VNS equally suppressed CSD susceptibility
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contralateral hemisphere lasting more than three hours after nVNS
application. These observations indicate that nVNS may interact
with the propagation of CSD as the electrophysiological correlate of
migraine aura [31,32]. To our knowledge, this is the first study
assessing peripheral HMGB-1 levels in human migraineurs,
although we observed no changes between all groups. In addition,
pooled assessment of migraine patients with aura compared to
those without aura demonstrated similar levels of peripheral
HMGB-1 levels for both groups.
A pre-obese state (BMI 20-25 kg/m2) was present in 16 partici-
pants and overweight (BMI 25-30 kg/m2) was present in four pa-
tients. However, we found no statistically significant changes for
leptin (pro-inflammatory), adiponectin (anti-inflammatory) and
ghrelin (anti-inflammatory) as BMI did not change. White adipose
tissue (WAT), previously associated with a metabolic storage
function, is now known to act as an inflammatory endocrine active
organwith the potential to induce or inhibit systemic inflammation
via crosstalk between adipocytes (e.g synthesis of leptin - adipo-
nectin) and the innate and adaptive immune system, linking
obesity to the pathogenesis of migraine [33e37]. For instance,
leptin (pro-inflammatory), a metabolic marker produced by WAT
cells, has been shown to interact with the COX-2 dependent
pathways via crosstalks with IL-1b in glial cells and neurons of the
hypothalamic-pituitary axis and ghrelin reduced photophobia and
induced behavioural changes in an experimental trigeminal pain
model [34,35]. Hence, immunometabolism may have a consider-
able impact on the molecular inflammatory profiling in migraine
patients. Rising evidence highlights the contribution of adipose
tissue in the development of systemic inflammatory associated
neurological disorders, of which some have been linked to obesity.
Circulating mediators of inflammation participate in the mecha-
nisms of migraine pathology, and many of these inflammatory
peptides are secreted from adipocytes and adipose tissueederived
immune cells (monocytes). The targeted inhibition of various pro-
inflammatory pathways in adipocytes may represent a novel
therapeutic approach for migraine [36,37].
Stimulation of the vagal nerve activates the cholinergic anti-
inflammatory reflex of neuro-immunity via its afferent properties
and reciprocal interaction with brainstem circuits leading to an
efferent response and changes in cytokine/chemokine levels. Acti-
vation of this anti-inflammatory reflex is assumed to induce pe-
ripheral inhibition of IL-1b, IL-6, TNF-a, HMGB-1 and other pro-
inflammatory mediators via a7 subunit of the nicotinic acetylcho-
line (Ach) receptor (a7nAchR) on immune cells (monocytes and
macrophages) [11e13,36,37].
Conclusion
Non-invasive vagus nerve stimulation significantly decreased
the number of severe attacks in our study, while there was no
statistical difference between sham and verum nVNS with respect
to migraine severity and migraine-associated co-morbidities. Sys-
temic circulating pro-inflammatory IL-1b was significantly
increased in sham-stimulated participants compared to verum
nVNS and anti-inflammatory IL-10 (anti-inflammatory) remained
significantly high before and after adjunctive verum nVNS treat-
ment, which may be indicative for head pain susceptibility. Pro-
and anti-inflammatory mediators such as IL-6, TNF-a, HMGB-1,
leptin, ghrelin and adiponectin remained unchanged.
The strengths of this proof-of-concept study is that it is the first
to investigate peripheral circulating cytokines suspected to be
involved in migraine development and chronification in human
migraineurs treated with nVNS. Main limitations include small
sample size, short-term observation period and the heterogenousstudy cohort as episodic and chronic migraine differs in patho-
physiology, prevalence, symptom phenotype, socio-demographics,
individual/economic burden and co-morbidities [16e19].
Furthermore, pre-analytical confounders may bias our findings.
In the future, blood-based phenotyping may help to identify
distinct pain phenotypes more likely to respond to neuro-
stimulation and facilitate the development of symptom-tailored
personalized neurostimulation treatment. Hence, our results,
though preliminary, certainly deserve to be further investigated in
large-scale and homogenized population studies. Ultimately,
biobank-based system biological approaches are on the way and
represent an appropriate roadmap to substantially provide insights
in such complex molecular circuits and the possible implications
for head pain therapy [38,39].
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